Clofibrate

This classification denotes an anti-lipidemic agent with the molecular formula C12H15ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HPN91K7FU3, chemically known as piperazine, 1- (diphenylmethyl)-4-(3-phenyl-2-propenyl)-, (e)- but generally known as clofibrate, which bears US NIH Compound Identifier 2761. European Medicines Agency schedules Clofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06706MIG. The term CLOFIBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules clofibrate in its Anatomical Therapeutic Chemical (ATC) Classification. CLOFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clofibrate under HS 29189900 and SITC 51396. As of Q4 2014, CLOFIBRATE remains the US FDA Preferred Term for this commodity. Clofibrate bears US NLM identifiers UMLS ID C0009002 and NCI Concept Code C378. SMILES: C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4.